# A Diagnostic Dilemma and Classification Conundrum: Atypical Histiocytic Neoplasm Presenting as a Calvarial Mass

**Authors:** Shabbir Haiderbhai, Leesha Heitkamp, Austin Nickell, Ellen Erie, Laura Nichols

PMC · DOI: 10.7759/cureus.54828 · Cureus · 2024-02-24

## TL;DR

An elderly woman's skull tumor presented with features not fitting standard histiocytic categories, leading to a classification as an atypical histiocytic disorder.

## Contribution

The paper presents a unique case of an atypical histiocytic neoplasm with conflicting diagnostic indicators.

## Key findings

- The patient's tumor showed cyclin D1 positivity and mutations in KRAS and GPS2.
- Clinical and histologic features did not align with any of the five established histiocytic categories.
- The case was classified as an atypical histiocytic disorder due to conflicting diagnostic evidence.

## Abstract

Histiocytic disorders are a wide range of disorders arising from abnormal proliferation and infiltration of dendritic cells. The Histiocyte Society has arranged the disorders into five main groups: L, C, M, R, and H. We present a case in which an elderly woman presented with a solitary osseous lesion in her skull in the right anterior calvarium. Biopsy and histological studies were strongly positive for cyclin D1; positive for CD68, S100, and ZBTB46; weakly positive for OCT2; and equivocal for ALK1 and CD163. Genomic studies also identified KRAS and GPS2 mutations. KRAS-positive genomic analysis favors a diagnosis of histiocytoma, while the solitary calvarium and spontaneous resolution with remission favor a diagnosis of Langerhans cell histiocytosis (LHC). Despite the strong clinical evidence favoring LCH, our patient’s clinical and histologic features did not fit any of the five histiocytic categories and were classified as an atypical histiocytic disorder.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], GPS2 (G protein pathway suppressor 2) [NCBI Gene 2874]
- **Proteins:** ccnd1.S (cyclin D1 S homeolog), CD68 (CD68 molecule), S100A1 (S100 calcium binding protein A1), ZBTB46 (zinc finger and BTB domain containing 46), POU2F2 (POU class 2 homeobox 2), ACVRL1 (activin A receptor like type 1), CD163 (CD163 molecule)
- **Diseases:** Langerhans cell histiocytosis (MONDO:0017025), histiocytoma (MONDO:0005509)

## Full-text entities

- **Genes:** POU2F2 (POU class 2 homeobox 2) [NCBI Gene 5452] {aka OCT2, OTF2, Oct-2}, GPS2 (G protein pathway suppressor 2) [NCBI Gene 2874] {aka AMF-1}, ZBTB46 (zinc finger and BTB domain containing 46) [NCBI Gene 140685] {aka BTBD4, BZEL, RINZF, ZNF340, dJ583P15.7, dJ583P15.8}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, SLPI (secretory leukocyte peptidase inhibitor) [NCBI Gene 6590] {aka ALK1, ALP, BLPI, HUSI, HUSI-1, HUSI-I}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}
- **Diseases:** Histiocytic disorders (MESH:D015620), histiocytoma (MESH:D051642), Calvarial Mass. (MESH:C537963), Histiocytic Neoplasm (MESH:D009369), LHC (MESH:D006646), osseous lesion (MESH:D000070896)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10963024/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10963024/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC10963024/full.md

---
Source: https://tomesphere.com/paper/PMC10963024